stockrowBioNexus Gene Lab Corp.
BGLCBasic Materials Specialty Chemicals
BioNexus Gene Lab Corp.’s revenue for fiscal 2025 (year ended December 2025) was $7.4 million, down 21.9% from fiscal 2024.
- Revenue
- −96.6%
- EPS
- +64.7%
- Free cash flow
- +44.3%
Quarter to June 2026, against a year earlier
Follow BGLC
Alert me
BioNexus Gene Lab Corp. (BGLC) Return on invested capital
BioNexus Gene Lab Corp.'s return on invested capital over the twelve months to 30 June 2026 was −37.2%, up 3.4 percentage points from fiscal 2025 (−40.5%). Over the past ten years it has ranged from −55.9% (fiscal 2019) to 20.4% (fiscal 2020); the current reading is higher than 38% of that period. That is below the Specialty Chemicals industry median of 3.21% and below the Basic Materials sector median of 0.75%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | −40.5% | (15.58) |
| FY2024 | −24.9% | 18.54 |
| FY2023 | −43.5% | (39.47) |
| FY2022 | −4.00% | (17.02) |
| FY2021 | 13.0% | (7.34) |
| FY2020 | 20.4% | 76.23 |
| FY2019 | −55.9% | (67.40) |
| FY2018 | 11.5% | — |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| NTIC Northern Technologies International Corporation compare | 2.03% |
| CNEY CN Energy Group. Inc. compare | 0.00% |
| YMAT J-Star Holding Co., Ltd compare | 0.00% |
| LOOP Loop Industries, Inc. compare | 0.00% |
| BON Bon Natural Life Limited compare | 0.00% |
| BGLC BioNexus Gene Lab Corp. | −37.2% |
| FEAM 5E Advanced Materials, Inc. compare | −60.7% |
| CITR CitroTech Inc. compare | −170.7% |
| SNES Senestech, Inc. compare | −416.4% |
| Specialty Chemicals industry median | 3.21% |
| Basic Materials sector median | 0.75% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)